Benlysta (belimumab) - GSK
Lupkynis (voclosporin) - Aurinia Pharma
cyclophosphamide - Generic mfg.
mycophenolate mofetil - Generic mfg.
Multi-targeted therapy better in achieving a complete response in Lupus Nephritis: A systematic review and meta-analysis (BSR 2024) - Mar 28, 2024 - Abstract #P060; "The highest effect was reported from study by Bao et.al using a combination of tacrolimus(TAC) and mycophenolate mofetil (MMF) compared to cyclophosphamide (CYC) (OR=10.5, 95% CI 2.27; 48.76), another study using TAC+MMF combo reported OR=2.49, 95% CI 1.59; 3.88...Studies using CYC, voclosporin + MMF, and belimumab also reported significant OR for achieving CR... Our meta-analysis suggests multi-target treatment strategies, by adding calcineurin inhibitors to MMF may be better for achieving complete response in LN. Furthermore, using this combination treatment did not seem to increase the risk of side effects. Heterogenous treatment response criteria and variable comparator arms were major limiting factors of this study." 
Retrospective data • Review • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
https://www.abstractsonline.com/pp8/#!/11005/presentation/1429
 
Omer Pamuk1; Bisma Shaikh2; Saif Khan3; Sarah Abi Doumeth4; Sarfaraz Hasni5
 
Mar 28, 2024
 
Prev Next